Omadacycline tosylate
Tier C — Watch / tradeOmadacycline tosylate · all drugs expiring in 2030 →
Targets：30S subunit
Brand：NUZYRA
Indications (approved)：Skin and skin structure infection, Community-acquired bacterial pneumonia, Bacterial infection, Bacterial pneumonia, Bacterial skin disease
Regional status
Factories producing this API2
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
2 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| OMAD-001 | 389140-04-9 | (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-9-iodo-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide |
| OMAD-002 | 488818-70-8 | (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-9-formyl-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide |
| OMAD-003 | 5813-64-9 | 2,2-dimethylpropan-1-amine |
| Code | CAS No. | Intermediate |
|---|---|---|
| OMAD-004 | 13614-98-7 | (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride |
| OMAD-005 | 118-29-6 | 2-(hydroxymethyl)isoindoline-1,3-dione |
| OMAD-006a | 835877-67-3 | - |
| OMAD-006b | - | (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-N,9-bis((1,3-dioxoisoindolin-2-yl)methyl)-10-((1,3-dioxoisoindolin-2-yl)oxy)-3,12,12a-trihydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide |
| OMAD-007 | 19532-98-0 | N1,N2-dimethylphthalamide |
| OMAD-008a | 488820-34-4 | - |
| OMAD-008b | 835877-68-4 | - |
| OMAD-009 | 630-19-3 | pivalaldehyde |
| Code | CAS No. | Intermediate |
|---|---|---|
| OMAD-003 | 5813-64-9 | 2,2-dimethylpropan-1-amine |
| OMAD-004 | 13614-98-7 | (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride |
| OMAD-010 | 162150-89-2 | 1,3,5-trineopentyl-1,3,5-triazinane |
| OMAD-011 | 541-88-8Available | 2-chloroacetic anhydride |
| OMAD-012 | 1075240-46-8 | (2-chloro-N-neopentylacetamido)methyl 2-chloroacetate |
| OMAD-013 | 1075240-41-3 | (4S,4aS,5aR,12aS)-9-((2-chloro-N-neopentylacetamido)methyl)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-N-(hydroxymethyl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide |
| OMAD-014 | - | (4aS,5aR,12aS)-9-((2-chloro-N-neopentylacetamido)methyl)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide |
Frequently asked questions
What are the approved indications of Omadacycline tosylate?
Approved indications include: Skin and skin structure infection, Community-acquired bacterial pneumonia, Bacterial infection, Bacterial pneumonia, Bacterial skin disease.
When does the Omadacycline tosylate patent expire?
Based on public sources, the Omadacycline tosylate patent expires in 2030.
How many synthesis routes are recorded for Omadacycline tosylate?
3 synthesis routes are recorded; the shortest is 2 steps with 5.41 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Omadacycline tosylate intermediates?
1 intermediate CAS of Omadacycline tosylate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Omadacycline tosylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29